Pharma BD Deal Intelligence
Novo Nordisk's $3.3B all-cash acquisition of Dicerna paid an 80% premium for a pre-revenue RNAi platform bet, and it paid off: lead asset nedosiran won FDA approval as RIVFLOZA in September 2023 for primary hyperoxaluria, later expanded to children as young as 2.
Novo Nordisk acquired Dicerna Pharmaceuticals for $3.3B for RNAi therapeutics.
Novo Nordisk snaps up partner Dicerna for $3.3 billion after their 2019 GalXC RNAi technology collaboration proved successful enough across 30+ liver cell…
FDA approves RIVFLOZA (nedosiran), a once-monthly GalXC RNAi therapy, for primary hyperoxaluria type 1 (PH1) -- the lead asset from the Dicerna acquisition…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Novo Nordisk acquired Dicerna Pharmaceuticals in an all-cash tender offer at $38.25/share (total equity value ~$3.3B, an ~80% premium), announced November 18, 2021 and completed December 28, 2021. The deal converted a 2019 research collaboration into full ownership of Dicerna's proprietary GalXC and GalXC-Plus RNAi platforms for liver-targeted gene silencing across cardiometabolic, NASH/liver, and rare disease targets. Dicerna was pre-revenue at deal time. The platform thesis was subsequently validated: Dicerna's lead GalXC asset nedosiran was FDA-approved as RIVFLOZA on September 29, 2023 under Novo Nordisk ownership for primary hyperoxaluria type 1 (PH1), and the label was later expanded to children aged 2 and older, giving Novo a marketed RNAi rare-disease product from the acquisition.
The GalNAc-siRNA hepatic-delivery space is dominated by Alnylam, whose platform generates the clear commercial benchmark. GalNAc-conjugated siRNA (direct overlap): Alnylam's Givlaari (givosiran) for acute hepatic porphyria, Oxlumo (lumasiran) for primary hyperoxaluria type 1, Leqvio (inclisiran, partnered with Novartis) for hypercholesterolemia, and Amvuttra (vutrisiran) for hATTR amyloidosis are all approved and collectively anchored Alnylam's $2.25B 2024 product revenue. Arrowhead Pharmaceuticals' TRiM platform produces plozasiran (APOC3, Phase 3 in FCS/SHTG) and zodasiran (ANGPTL3), while Silence Therapeutics' mxRNA platform delivered divesiran (Phase 2 polycythemia vera). ASO hepatic alternatives: Ionis/Akcea's Waylivra (volanesorsen) and tofersen (Qalsody) represent the established antisense class but lack the durability of GalNAc-siRNA. Extrahepatic siRNA (GalXC-Plus zone): Alnylam's CNS program cemdisiran and Arrowhead's pulmonary/adipose TRiM constructs compete for tissues Dicerna's platform targets. Commercially, Novo Nordisk's rationale is cardiometabolic extension — Leqvio already proves the category can reach primary-care scale ($754M 2024 sales), but Alnylam's first-mover breadth across rare liver disease establishes the competitive ceiling Novo must breach to justify the $3.3B price. Dicerna's differentiation rests on extrahepatic reach and protease-resistant chemistry.
Same cardiometabolic RNAi context as indication_id 62c3bd32 — this is a duplicate row in the Novo/Dicerna indication tagging. Competitive context: Alnylam inclisiran (Leqvio), olpasiran, zilebesiran; Arrowhead ARO-ANG3 (ANGPTL3); Ionis olezarsen (ApoCIII). Recommend deduplicating the three Cardiometabolic Disorders rows on this deal.
Primary hyperoxaluria (PH) is an ultra-rare genetic disorder (~1 in 120,000, ~3,000-5,000 diagnosed patients in US/EU combined) with a two-drug GalNAc-siRNA duopoly competing on dosing interval, genotype coverage, and pediatric label. GalNAc-siRNA targeting GO (glycolate oxidase): lumasiran (Oxlumo, Alnylam) — FDA-approved November 2020 for PH1 across all ages including infants, generating $127M in 2023 per Alnylam IR; subcutaneous monthly then every 3 months dosing; first-to-market and the category leader. GalNAc-siRNA targeting LDHA (downstream enzyme): nedosiran (Rivfloza, Dicerna/Novo Nordisk) — FDA-approved September 2023 for PH1 in adults and children >=9 years; once-monthly subcutaneous dosing; commercial ramp in 2024. Nedosiran was initially developed for PH1/2/3 but Phase 3 PHYOX2 met endpoint only in PH1. Standard-of-care baseline (pre-RNAi era, still used): high-dose pyridoxine (vitamin B6, generic) responsive in ~30% PH1 patients; aggressive hydration and urinary citrate; combined liver-kidney transplantation for end-stage disease. Investigational: gene therapy (AAV AGXT) remains preclinical; CRISPR-edited autologous hepatocytes academic stage. Commercial lead takeaway: Rivfloza must carve share from Oxlumo's first-mover advantage through dosing convenience, payer positioning, and potential real-world efficacy signals. Combined PH1 franchise ceiling ~$500-700M annually given prevalence; Rivfloza realistic peak $150-250M.
Novo Nordisk completed $3.3B acquisition of Dicerna Pharmaceuticals, gaining GalXC RNAi technology platform for liver-targeted therapeutics.
Dicerna's GalXC RNAi platform integrated into Novo Nordisk cardiometabolic R&D, advancing multiple candidates in liver-targeted gene silencing.
Dicerna's lead GalXC asset nedosiran won FDA approval as RIVFLOZA for primary hyperoxaluria type 1, validating the platform Novo Nordisk acquired and delivering a marketed RNAi product.
GalXC gives Novo Nordisk proprietary RNAi capabilities complementing GLP-1 franchise. Pipeline advancing but no approved products yet from the platform.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. (this deal) | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 58 |
← Browse all deals · How we score deals
More: 2021 deals · Novo Nordisk A/S deals · Metabolic deals